A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review

Wilder, Lisa Van; Rammant, Elke; Clays, Els; Devleesschauwer, Brecht; Pauwels, N.; Smedt, Delphine De

doi:10.1007/s11136-019-02300-y

Cited by 55 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The EQ‐5D family of instruments consists of two parts: the descriptive system, which comes in three versions, including EQ‐5D‐3L (3L), EQ‐5D‐5L (5L), and EQ‐5D‐Y (Youth); and a VAS (EQ VAS). The EQ 5D and EQ‐VAS can be used in clinical trials, population health surveys, routine outcome measurement, and many other types of studies in which a generic measure of health status is useful . The descriptive system can be presented as a health profile or converted to a single summary index value that reflects health state preferences by using data from the general population.…”

Section: Eq‐5d and Eq Vasmentioning

confidence: 99%

“…The EQ VAS score (range: 0‐100) represents an individual's perspective of their own health state and is appropriate for use in clinical practice and research. In contrast, EQ‐5D utility scores are linked to a general population's perspective about the value of a health state and are preferred in health economic analyses . However, compared with the 3L, the 5L mean utility scores move up toward best imaginable health and condenses mean scores into a smaller range .…”

Section: Eq‐5d and Eq Vasmentioning

confidence: 99%

“…The EQ‐5D instruments are useful in a broad range of health conditions (including, but not limited to, rheumatology), settings, and countries . EQ‐5D utility scores can be used to compare treatment effectiveness and cost‐effectiveness across a variety of different conditions and settings.…”

Section: Eq‐5d and Eq Vasmentioning

confidence: 99%

See 2 more Smart Citations

Adult Measures of General Health and Health‐Related Quality of Life

Busija

Ackerman

Haas

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Section: Eq‐5d and Eq Vasmentioning

confidence: 99%

Section: Eq‐5d and Eq Vasmentioning

confidence: 99%

See 1 more Smart Citation

Adult Measures of General Health and Health‐Related Quality of Life

Busija

Ackerman

Haas

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

“…Based on an extensive literature search, disutilities per AE were constructed (online supplementary table 2). 15–24 If no specific disutility was found, a general moderate-intensity treatment associated disutility (0.002) was applied 25…”

Section: Methodsmentioning

confidence: 99%

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

et al. 2020

View full text Add to dashboard Cite

ObjectivesTo evaluate the cost-effectiveness of treat-to-target strategies among recently diagnosed patients with rheumatoid arthritis (RA) using methotrexate (MTX) and a step-down glucocorticoid (GC) scheme (COBRA Slim) compared with (1) this combination with either sulphasalazine (COBRA Classic) or leflunomide (COBRA Avant-Garde) in high-risk patients and (2) MTX without GCs (Tight-Step-Up, TSU) in low-risk patients.MethodsThe incremental cost-utility was calculated from a healthcare perspective in the intention-to-treat population (n=379) of the 2-year open-label pragmatic randomised controlled Care in early RA trial. Healthcare costs were collected prospectively through electronic trial records. Quality-adjusted life years (QALYs) were estimated using mapping algorithms for EuroQoL-5 Dimension. Multiple imputation was used to handle missing data and bootstrapping to calculate CIs. Robustness was tested with biological disease-modifying antirheumatic drugs at biosimilar prices.ResultsIn the high-risk group, Classic (∆k€1.464, 95% CI −0.198 to 3.127) and Avant-Garde (∆k€0.636, 95% CI −0.987 to 2.258) were more expensive compared with Slim and QALYs were slightly worse for Classic (∆−0.002, 95% CI −0.086 to 0.082) and Avant-Garde (∆−0.009, 95% CI −0.102 to 0.084). This resulted in the domination of Classic and Avant-Garde by Slim. In the low-risk group, Slim was cheaper (∆k€−0.617, 95% CI −2.799 to 1.566) and QALYs were higher (∆0.141, 95% CI 0.008 to 0.274) compared with TSU, indicating Slim dominated. Results were robust against the price of biosimilars.ConclusionsThe combination of MTX with a GC bridging scheme is less expensive with comparable health utility than more intensive step-down combination strategies or a conventional step-up approach 2 years after initial treatment.Trial registration numberNCT01172639.

show abstract

“…Moreover, the use of different tools for measuring HRQoL may also lead to the identi cation of different factors associated with HRQoL [9]. The European Quality of Life Five Dimensions (EQ-5D), is one of the most commonly prefered generic tools to assess HRQoL in different patients; the EQ-5D 5 Level (EQ-5D-5L) can reduce the ceiling effect more than the EQ-5D-3L, and has some psychometric advantages compared with the EQ-5D-3L in measuring some generic health outcomes in stroke patients [10][11][12]. However, most researchers focused on only the in uencing factors of the total EQ-5D score, and paid little attention to the in uencing factors of each domain score.…”

Section: Introductionmentioning

confidence: 99%

EQ-5D results in stroke survivors: What are they suffering from? Results from the Henan Rural Cohort Study

Mei

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Stroke is a major health threat and the leading cause of mortality and disability in China. The aims of this study were to identify the possible influencing factors of health-related quality of life (HRQoL) and its domain-specific contents in stroke patients in rural areas in China. Methods A total of 1709 stroke patients aged from 36 to 79 years from the Henan Rural Cohort Study (n=39259) were included in this study. The Chinese version of the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) and visual analogue scale (VAS) were used to evaluate HRQoL in stroke patients. Tobit regression models, generalized linear models and binary logistic regressions models were constructed to determine the potential influencing factors of the EQ-5D utility index, as well as influencing factors of each domains and VAS score.Results The mean utility index and VAS scores of stroke patients were 0.885 (SD, 0.204), and 68.39 (SD, 17.31), respectively. Pain/discomfort (PD, 35.2%) and mobility (MO, 30.4%) were the most frequently reported issues. Regression models revealed that stroke patients who were illiterate; had a low monthly income; reported low physical activity intensity; and had diabetes, anxiety, depression or poor sleep quality had lower utility index and VAS scores. For the different dimensions of the EQ-5D, the influencing factors varied. Conclusion Stroke patients in rural areas had a lower HRQoL than those in urban areas. Factors associated with the EQ-5D utility index as well as each domain and VAS score, need attention. Stroke patients in rural areas need to be managed systematically. Clinical trial registration: The Henan Rural Cohort Study has been registered in the Chinese Clinical Trial Register (Registration Number: ChiCTR-OOC-15006699). Date of registration: 2015-07-06.http://www.chictr.org.cn/showproj.aspx?proj=11375.

show abstract

A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review

Cited by 55 publications

References 35 publications

Adult Measures of General Health and Health‐Related Quality of Life

Adult Measures of General Health and Health‐Related Quality of Life

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

EQ-5D results in stroke survivors: What are they suffering from? Results from the Henan Rural Cohort Study

Contact Info

Product

Resources

About